抗血管生成药物联合免疫检查点抑制剂治疗晚期非小细胞肺癌的协同作用机制及临床研究的新进展

Synergistic mechanism and progress in clinical research of anti-angiogenic drugs combined with immune checkpoint inhibitors for advanced non-small cell lung cancer

抗血管生成和免疫治疗是肺癌治疗的重要方法。抗血管生成治疗可以阻止肿瘤血管的形成,增加免疫细胞的浸润,将肿瘤微环境从免疫抑制转变为免疫支持。免疫治疗可以提高机体的免疫功能,也可以促进血管“正常化”。抗血管生成药物和免疫检查点抑制剂具有协同作用。本文就抗血管生成联合免疫治疗的理论基础以及该联合策略在晚期非小细胞肺癌的研究进展进行综述。

Anti-angiogenic therapy and immunotherapy are important methods in the treatment of lung cancer.Anti-angiogenic therapy can prevent the formation of tumor blood vessels,increase the infiltration of immune cells,transform tumor microenvironment from immune suppression to immune support.Immunotherapy can improve the body’s immune function and promote vascular normalization.Anti-angiogenic drugs and immune checkpoint inhibitors have synergistic effects.This article reviewed the theoretical basis of anti-angiogenic therapy combined immunotherapy and the research progress of this combined strategy for advanced non-small cell lung cancer.